Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/146637
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Londoño, María Carlota | - |
dc.contributor.author | Riveiro Barciela, Mar | - |
dc.contributor.author | Ahumada, Adriana | - |
dc.contributor.author | Muñoz Gómez, Raquel | - |
dc.contributor.author | Roget, Mercé | - |
dc.contributor.author | Devesa Medina, María J. | - |
dc.contributor.author | Serra, Miguel Ángel | - |
dc.contributor.author | Navascués, Carmen A. | - |
dc.contributor.author | Baliellas Comellas, Mª Carme | - |
dc.contributor.author | Aldamiz, Teresa | - |
dc.contributor.author | Gutiérrez, María L. | - |
dc.contributor.author | Polo Lorduy, Benjamín | - |
dc.contributor.author | Carmona, Isabel | - |
dc.contributor.author | Benlloch, Salvador | - |
dc.contributor.author | Bonet, Lucía | - |
dc.contributor.author | García Samaniego, Javier | - |
dc.contributor.author | Jiménez Pérez, Miguel | - |
dc.contributor.author | Morán Sánchez, Senador | - |
dc.contributor.author | Castro, Ángeles | - |
dc.contributor.author | Delgado, Manuel | - |
dc.contributor.author | Gea Rodríguez, Francisco | - |
dc.contributor.author | Martín Granizo, Ignacio | - |
dc.contributor.author | Montes, María Luisa | - |
dc.contributor.author | Morano, Luís | - |
dc.contributor.author | Castaño, Manuel A. | - |
dc.contributor.author | Santos, Ignacio de los | - |
dc.contributor.author | Laguno Centeno, Montserrat | - |
dc.contributor.author | Losa, Juan Emilio | - |
dc.contributor.author | Montero-Alonso, Marta | - |
dc.contributor.author | Rivero, Antonio | - |
dc.contributor.author | Álvaro, Cristina de | - |
dc.contributor.author | Manzanares, Amanda | - |
dc.contributor.author | Mallolas Masferrer, Josep | - |
dc.contributor.author | Barril, Guillermina | - |
dc.contributor.author | González Parra, Emilio | - |
dc.contributor.author | García Buey, Luisa | - |
dc.date.accessioned | 2019-12-13T10:53:54Z | - |
dc.date.available | 2019-12-13T10:53:54Z | - |
dc.date.issued | 2019-09-24 | - |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.uri | http://hdl.handle.net/2445/146637 | - |
dc.description.abstract | Limited data are available on the effectiveness and tolerability of direct-acting antivirals (DAAs) therapies in the real world for HCV-infected patients with comorbidities. This study aimed to describe the effectiveness of OBV/PTV/r ± DSV (3D/2D regimen) with or without ribavirin (RBV) in HCV or HCV/HIV co-infected patients with GT1/GT4 and CKD (IIIb-V stages), including those under hemodialysis and peritoneal dialysis in routine clinical practice in Spain in 2015.Non-interventional, retrospective, multicenter data collection study in 31 Spanish sites. Socio-demographic, clinical variables, study treatment characteristics, effectiveness and tolerability data were collected from medical records.Data from 135 patients with a mean age (SD) of 58.3 (11.4) years were analyzed: 92.6% GT1 (81.6% GT1b and 17.6% GT1a) and 7.4% GT4, 14 (10.4%) HIV/HCV co-infected, 19.0% with fibrosis F3 and 28.1% F4 by FibroScan®, 52.6% were previously treated with pegIFN and RBV. 11.1%, 14.8% and 74.1% of patients had CKD stage IIIb, IV and V respectively. 68.9% of patients were on hemodialysis; 8.9% on peritoneal dialysis and 38.5% had history of renal transplant. A total of 125 (96.2%) of 135 patients were treated with 3D, 10 (7.4%) with 2D and 30.4% received RBV. The overall intention-to-treat (ITT) sustained virologic response at week 12 (SVR12) was 92.6% (125/135) and the overall modified-ITT (mITT) SVR12 was 99.2% (125/126). The SVR12 rates (ITT) per sub-groups were: HCV mono-infected (91.7%), HCV/HIV co-infected (100%), GT1 (92.0%), GT4 (100%), CKD stage IIIb (86.7%), stage IV (95%) and stage V (93%). Among the 10 non-SVR there was only 1 virologic failure (0.7%); 4 patients had missing data due lost to follow up (3.0%) and 5 patients discontinued 3D/2D regimen (3.7%): 4 due to severe adverse events (including 3 deaths) and 1 patient´s decision.These results have shown that 3D/2D regimens are effective and tolerable in patients with advanced CKD including those in dialysis with GT 1 or 4 chronic HCV mono-infection and HIV/HCV coinfection in a real-life cohort. The overall SVR12 rates were 92.6% (ITT) and 99.2% (mITT) without clinically relevant changes in eGFR until 12 weeks post-treatment. These results are consistent with those reported in clinical trials. | - |
dc.format.extent | 14 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Public Library of Science (PLoS) | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0221567 | - |
dc.relation.ispartof | PLoS One, 2019, vol. 14, num. 9, p. e0221567 | - |
dc.relation.uri | https://doi.org/10.1371/journal.pone.0221567 | - |
dc.rights | cc by (c) Londoño et al., 2019 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | - |
dc.source | Articles publicats en revistes (Medicina) | - |
dc.subject.classification | Malalties del ronyó | - |
dc.subject.classification | Hepatitis C | - |
dc.subject.other | Kidney diseases | - |
dc.title | Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2019-12-10T08:21:10Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.idimarina | 5865124 | - |
dc.identifier.pmid | 31550267 | - |
Appears in Collections: | Articles publicats en revistes (Medicina) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
12474_5865124_journal.pone.0221567.pdf | 853.67 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License